Health · 1 sources covering this

STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns

Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/6f78e3c48e5bdbe701d59afc689140f540a697ee"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns"></iframe>

STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns

How 1 sources are covering this

STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns

More from Health

STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts

STAT+: Global coalition to fast-track three vaccines targeting Ebola outbreak with $62 million in funding

STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

STAT+: At the world’s largest cancer research meeting, data briefly took a backseat to grief

Reader

Trust & legal

Across the network